Norgine welcomes TGA registration in Australia of PEDMARQSI® (sodium thiosulfate anhydrous) for the prevention of cisplatin-induced hearing loss in children1
PEDMARQSI ® is now TGA registered in Australia for the prevention of ototoxicity induced by cisplatin chemotherapy in patients 1 month to <18 years of age with localised, non-metastatic, solid tumours TGA registration provides an approved...
Norgine strengthens rare disease portfolio with acquisition of Theravia
Acquisition of Theravia from Merieux Equity Partners represents meaningful step forward in Norgine's strategy for sustainable growth, adding a complementary portfolio of rare disease medicines Transaction further establishes Norgine's position as a...